Ixazomib [MLN2238]

Potent selective and reversible proteasome inhibitor (all proteolytic subunits).
Targets the chymotrypsin-like β5 subunit of the constitutive 20S proteasome (IC50=3.4nM). Cross-reacts and inhibits the trypsin-like β2 subunit (IC50=3.5μM) and the caspase-like/peptidyl-glutamyl peptide-hydrolyzing (PGPH) β1 subunit (IC50=0.03μM).
Anticancer compound effective in cell-based assays, in xenografts and against multiple myeloma in vivo.
In vitro, induces cell cycle arrest and apoptosis in human cancer cell lines including multiple myeloma.
Biologically active form of the prodrug MLN9708 (Prod. No. AG-CR1-3671).
Exhibits improved pharmacodynamics and antitumor activity compared to bortezomib (Prod. No. AG-CR1-3602) in various B cell lymphoma models, due to a greater tumor to blood ratio of proteasome inhibition that ultimately translates into improved tumor pharmacodynamic response and antitumor activity in several tumor xenograft models.